Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15.84 USD | -0.60% | -1.06% | -38.95% |
08:35pm | CVS Store-Brand Medications Face Quality Concerns and Higher Recall Rates | MT |
Jun. 10 | Global markets live: ABB, Roche, Microsoft, Apple, Tesla... |
Summary
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company shows low valuation levels, with an enterprise value at 0.14 times its sales.
- The company appears to be poorly valued given its net asset value.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- The company is one of the best yield companies with high dividend expectations.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-38.95% | 13.75B | B- | ||
-36.57% | 10.33B | B | ||
-10.38% | 7.94B | B | ||
+4.30% | 5.86B | C | ||
-14.62% | 5.69B | C+ | ||
-3.21% | 4.65B | D- | ||
+69.95% | 4.46B | C | ||
-8.55% | 3.79B | B | ||
-22.93% | 3.05B | C- | ||
-14.25% | 2.83B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- WBA Stock
- Ratings Walgreens Boots Alliance, Inc.